Preclinical xenograft models of human sarcoma show nonrandom loss of aberrations - PubMed (original) (raw)
. 2012 Jan 15;118(2):558-70.
doi: 10.1002/cncr.26276. Epub 2011 Jun 28.
Affiliations
- PMID: 21713766
- DOI: 10.1002/cncr.26276
Free article
Preclinical xenograft models of human sarcoma show nonrandom loss of aberrations
Stine H Kresse et al. Cancer. 2012.
Free article
Abstract
Background: Human tumors transplanted into immunodeficient mice (xenografts) are good preclinical models, and it is important to identify possible systematic changes during establishment and passaging in mice.
Methods: High-resolution microarray-based comparative genomic hybridization (array CGH) was used to investigate how well a series of sarcoma xenografts, including 9 patient/xenograft pairs and 8 early versus late xenograft passage pairs, represented the patient tumor from which they originated.
Results: In all analyses, the xenografts were more similar to their tumor of origin than other xenografts of the same type. Most changes in aberration patterns were toward a more normal genome complement, and the increased aberrations observed were mostly toward more loss. In general, the changes were scattered over the genome, but some changes were significant in osteosarcomas. These were rather focused and consistent with amplifications frequent in patient samples, involving the genes platelet-derived growth factor receptor A (PDGFRA), cysteine-rich hydrophobic domain 2 (CHIC2), FIP-like 1 (FIP1L1), ligand of numb-protein X1 (LNX1), RAS-like family 11 member B (RASL11B), and sec1 family domain containing 2 (SCFD2), probably a sign of continued tumor progression. Some changes that disappeared may have been involved in host-stroma interactions or chemotherapy resistance, possibly because of the absence of selection in the mouse.
Conclusions: Direct xenografts reflected well the genomic patterns of their tumors of origin. The few significant aberrations that were lost during passaging in immune-defective mice may have been caused by the lack of selection in the new host, whereas aberrations that were gained appeared to be the result of general tumor progression rather than model-specific artifacts.
Copyright © 2011 American Cancer Society.
Similar articles
- Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes.
Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M, English J, Flint J, LeRiche J, Yee J, Squire JA, Gout PW, Lam S, Wang YZ. Cutz JC, et al. Clin Cancer Res. 2006 Jul 1;12(13):4043-54. doi: 10.1158/1078-0432.CCR-06-0252. Clin Cancer Res. 2006. PMID: 16818704 - Establishment and characterization of human urothelial cancer xenografts in severe combined immunodeficient mice.
Abe T, Tada M, Shinohara N, Okada F, Itoh T, Hamada J, Harabayashi T, Chen Q, Moriuchi T, Nonomura K. Abe T, et al. Int J Urol. 2006 Jan;13(1):47-57. doi: 10.1111/j.1442-2042.2006.01220.x. Int J Urol. 2006. PMID: 16448432 - Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization.
Laitinen S, Karhu R, Sawyers CL, Vessella RL, Visakorpi T. Laitinen S, et al. Genes Chromosomes Cancer. 2002 Sep;35(1):66-73. doi: 10.1002/gcc.10097. Genes Chromosomes Cancer. 2002. PMID: 12203791 - The use of xenograft models for the selection of cancer treatments with the EGFR as an example.
Troiani T, Schettino C, Martinelli E, Morgillo F, Tortora G, Ciardiello F. Troiani T, et al. Crit Rev Oncol Hematol. 2008 Mar;65(3):200-11. doi: 10.1016/j.critrevonc.2007.10.003. Crit Rev Oncol Hematol. 2008. PMID: 18389522 Review. - Preclinical models for translational sarcoma research.
Hamacher R, Bauer S. Hamacher R, et al. Curr Opin Oncol. 2017 Jul;29(4):275-285. doi: 10.1097/CCO.0000000000000373. Curr Opin Oncol. 2017. PMID: 28445233 Review.
Cited by
- Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer.
Morton JJ, Keysar SB, Perrenoud L, Chimed TS, Reisinger J, Jackson B, Le PN, Nieto C, Gomez K, Miller B, Gao D, Somerset H, Wang XJ, Jimeno A. Morton JJ, et al. Mol Carcinog. 2018 Nov;57(11):1651-1663. doi: 10.1002/mc.22887. Epub 2018 Sep 3. Mol Carcinog. 2018. PMID: 30129680 Free PMC article. - Establishment and characterization of patient-derived xenograft and its cell line of primary leiomyosarcoma of bone.
Oyama R, Takahashi M, Kito F, Sakumoto M, Shiozawa K, Qiao Z, Yoshida A, Endo M, Kawai A, Kondo T. Oyama R, et al. In Vitro Cell Dev Biol Anim. 2018 Jun;54(6):458-467. doi: 10.1007/s11626-018-0258-2. Epub 2018 May 29. In Vitro Cell Dev Biol Anim. 2018. PMID: 29845452 - Xenografting Human Musculoskeletal Sarcomas in Mice, Chick Embryo, and Zebrafish: How to Boost Translational Research.
Giusti V, Miserocchi G, Sbanchi G, Pannella M, Hattinger CM, Cesari M, Fantoni L, Guerrieri AN, Bellotti C, De Vita A, Spadazzi C, Donati DM, Torsello M, Lucarelli E, Ibrahim T, Mercatali L. Giusti V, et al. Biomedicines. 2024 Aug 21;12(8):1921. doi: 10.3390/biomedicines12081921. Biomedicines. 2024. PMID: 39200384 Free PMC article. Review. - Osteosarcoma models: from cell lines to zebrafish.
Mohseny AB, Hogendoorn PC, Cleton-Jansen AM. Mohseny AB, et al. Sarcoma. 2012;2012:417271. doi: 10.1155/2012/417271. Epub 2012 Mar 15. Sarcoma. 2012. PMID: 22566751 Free PMC article. - Validation of a preclinical model for assessment of drug efficacy in melanoma.
Delyon J, Varna M, Feugeas JP, Sadoux A, Yahiaoui S, Podgorniak MP, Leclert G, Dorval SM, Dumaz N, Soulie J, Janin A, Mourah S, Lebbé C. Delyon J, et al. Oncotarget. 2016 Mar 15;7(11):13069-81. doi: 10.18632/oncotarget.7541. Oncotarget. 2016. PMID: 26909610 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous